معرفی
Anton Reepalu is affiliated with Lund University as a Researcher in Clinical Infection Medicine. His work focuses on HIV treatment outcomes in low-resource settings, tuberculosis co-infections, and post-COVID-19 patient recovery. He leads the RifRSA study on rifampicin resistance in Staphylococcus aureus and collaborates on projects addressing syphilis epidemiology in Skåne. His research aligns with UN SDG targets for global health equity.
Research interests include antiretroviral therapy efficacy, healthcare system challenges in Sub-Saharan Africa, and ICU survivorship. He has contributed to 24 peer-reviewed publications since 2020, with recent work in Acta Anaesthesiologica Scandinavica and Global Health Action.
- Leads the 2021–2026 RifRSA project investigating antibiotic resistance
- Co-leads the THESA project in Ethiopia since 2022
- Principal Investigator for ACE2-COVID19 research since 2020
Active in multidisciplinary collaborations across Sweden and Ethiopia, his work combines clinical practice with public health policy implications.
